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OBJECTIVE: To investigate the biological behavior of classical and atypical osteoblastomas in comparison to osteosarcomas.
METHODS: Based on histological parameters, 30 osteoblastomas were subclassified as classical osteoblastomas (23/30) or
atypical osteoblastoma (high cellularity, prominent blue osteoid, and epithelioid osteoblasts–7/30). Comparative
immunohistochemical and clinical analysis was performed in 17 cases of patients with high-grade osteosarcoma. Formalin-fixed,
paraffin-embedded archival tissue was immunostained for p53 and proliferation cell nuclear antigen. Tumors with positive p53
stain underwent molecular analyses for fragments of exon 10.
RESULTS: The mean proliferating cell nuclear antigen indexes for classical osteoblastoma, atypical osteoblastoma, and
osteosarcoma were 33%, 61%, and 79%, respectively. The atypical subgroup showed similar results to those of the osteosarcoma
group (P < 0.001). p53 protein was detected in 4 (13%) osteoblastomas (3 of these were atypical osteoblastoma), and 4 osteosarcomas
(23%) also showed p53 positivity. DNA mutation performed in p53-positive cases was confirmed in exon 10 in 2 atypical
osteoblastomas (2/3), 1 classical osteoblastoma (1/1), and 1 osteosarcoma (1/4). Disease recurrence was correlated with p53
expression (P = 0.009), atypical subtype (P = 0.031), spiculated blue bone on histology (P = 0.018), and proliferating cell nuclear
antigen labeling index ≥ 40 (P = 0.015).
CONCLUSION: These results validate atypical osteoblastoma as an entity, with p53 and proliferation cell nuclear antigen
immunoexpression closer to that of osteosarcoma than of classical osteoblastoma. Proliferating cell nuclear antigen labeling
index and p53 may be useful predictors of recurrence.
KEYWORDS: Bone neoplasms. Cell proliferation. Proliferating cell nuclear antigen. Immunohistochemistry. Osteoblastoma.
p53 gene. p53 protein.
INTRODUCTION
Osteoblastoma is an uncommon bone tumor that is
considered the benign counterpart of osteosarcoma. Locally
aggressive behavior has been noted in some osteoblastomas;
however, malignant transformation of the tumors ia rare.1–5
Malignant osteoblastoma or aggressive osteoblastoma,6,7 are
terms used to describe some lesions that show atypical
cytologic features and may be correlated with recurrence.
Osteoblastoma accounts for approximately 1% of all bone
tumors.8,9 The most commonly affected sites are the spine,
the diaphyses of long bones, pelvis, talus, facial bones, and
short bones of the hands and feet. Most of the patients af-
fected by osteoblastoma are in the second or third decades
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of life.1 Approximately 25% of patients have radiographic
and histologic aspects that may suggest malignancy,10 such
as large epithelioid osteoblasts, bizarre cells, mitosis, and
lace- or sheet-like osteoid production. Several reports6,7,11
have proposed a designation of a borderline osteoblastic
tumor, whose radiographic and histologic features vary be-
tween the osteoblastoma and osteosarcoma. The term ag-
gressive osteoblastoma was considered preferable because
it designates a tumor with local destructive behavior, but
without metastatic potential. According to several studies,
osteoblastomas may primarily undergo malignant transfor-
mation.1,2,4,5 Moreover, cases of osteoblastoma-like osteosa-
rcoma are well-recognized.12,13 Further reports of large se-
ries of osteoblastomas have not confirmed the predictive
value of the microscopic appearances,1,14 raising the ques-
tion of whether atypical osteoblastoma really does exist.
The assessment of the proliferative antigen expression
yields predictive indicators in soft tissues and bone tumors,
with several studies demonstrating the clinical value of anti-
PCNA (proliferating cell nuclear antigen) and anti-p53
monoclonal antibodies in these tumors.15–19 Immunohisto-
chemical expression of the p53 protein and the analysis of
p53 gene mutations have also been described in 10% to
35% of soft tissue tumors.18 However, only few studies have
reported the importance of p53 changes in borderline or
low-grade osteoblastic tumors, with controversial results.20–
22
 Rossner et al23 reported mutation of the p53 gene at exon
5 in a patient with malignant osteoblastoma. Radig et al20
described another mutation at exon 7 in a patient with
osteoblastoma-like osteosarcoma. Luca et al24 have previ-
ously reported abnormalities in exon 10 of the p53 gene
of osteosarcomas, suggesting that exon 10, which is prob-
ably involved in the protein oligomerization, is essential
for protein function.
The aim of this study was to contribute to understand-
ing this rare bone neoplasm based on morphology, prolif-
eration rate, and p53 mutation analysis. In addition, high-




A retrospective review of 30 patients with
osteoblastoma who were treated at the Instituto de
Ortopedia e Traumatologia of the São Paulo University
Medical School Hospital was performed. The group of pa-
tients evaluated consisted of 19 men and 11 women, and
the median age was 18.5 years (range, 4-41 years). The
most commonly affected sites were the spine (33%) and
the long bones of the appendicular skeleton (23%). Typi-
cally, a radiolucent and well-circumscribed expansive le-
sion with calcifications was observed (Figure 1). Seventeen
patients with high-grade osteosarcomas were evaluated in
order to compare results from immunohistochemical and
molecular analyses. In all patients, hematoxylin-eosin–
stained sections confirmed the diagnosis. Tumors were clas-
sified as atypical osteoblastomas (n = 7) according to the
histologic features described by Schajowicz and Lemos7
and Dorfman.6 Schajowicz and Lemos7 proposed the term
malignant osteoblastoma for lesions that present with high
cellularity, nuclear atypia, and immature tumor bone (spicu-
lated blue bone). Dorfman and Weiss6 proposed the term
aggressive osteoblastoma for lesions that present with cel-
lular zones of epithelioid osteoblasts. Radiographic find-
ings and follow-up were documented based on the clinical
records.
Immunohistochemistry (IHQ)
Deparaffinized formalin-fixed sections were
immunostained using monoclonal antibodies to the p53 pro-
tein (DO7, 1:2000, DAKO Corporation) and PCNA (PC10,
1:8000, DAKO Corporation). Sections underwent heat-in-
duced epitope retrieval using a pressure-cooker. Antigens
were identified using the strepta-avidin-biotin method. For
p53, positivity was defined as ≥ 10% of immunostained
tumor cells.25 The percentage of tumoral cells positive for
PCNA was determined from 500 tumor cells, and results
were expressed as PCNA labeling index (PCNA-LI).
Molecular Analyses
Preparing DNA (deoxyribonucleic acid)
Genomic DNA was isolated from the archival paraffin-
embedded material from the 4 cases of osteoblastoma and
Figure 1 - Osteoblastoma of the distal humerus showing cortical expansion
(Case 25, atypical osteoblastoma)
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the 4 cases of osteosarcoma with positive immunohisto-
chemistry for the p53 protein. Paraffin-block sections from
tumor tissues were stained by hematoxylin-eosin to select
areas of neoplastic and normal tissues. According to pre-
viously published guidelines,26 DNA extraction was per-
formed using paraffin-embedded tissue with the standard
phenol chloroform extraction method.
Polymerase chain reaction (PCR)
PCR was used to amplify DNA fragments. In all cases,
genomic DNA was amplified using a 100-µL PCR mixture
of oxynucleotide triphosphate (100 µmol/L), MgCl2 (50
mmol/L), 10 pmol of each of the primers, and Taq polymer-
ase (2.5 U) (Pharmacia Biotech, Uppsala, Sweden). Ther-
mal cycling was performed using a Gene Amp PCR Sys-
tem (Perkin Elmer Cetus, Norwalk, CT). Polymerase chain
reaction was done at 94°C for 5 minutes followed by a 30-
cycle denaturation at 94°C for 5 minutes, and a 30-cycle
denaturation at 94°C for 30 seconds. In all PCR experi-
ments, reactions without DNA were considered negative
controls. All PCR products were visualized using 2%
ethidium bromide-stained agarose gels. Fragments of exon
10, exon 5, and exon 7 of the p53 with 195 bp were am-
plified using 2 pairs of oligonucleotide.23
Exon 5: 5’ A T C T G T T C A C T T G T G C C C T G A
C T T T C 3’ and 5’ A C C C T G G G C A A C C A G C
C C T G T 3’
Exon 10: 5’ G C T G TA T A G G T A C T T G A A G T G
C 3’ and 5’ C A T A G G A T T C C A T T C T C A T C 3’
Exon 7: C T C C T A G G T T G G C T C T G 3’ and 5’ G
A G G C T G G G G C A C A G C A G G C C A G T G 3’
Direct Sequencing
Polymerase chain reaction products were prepared for
DNA sequencing using exonuclease enzyme (Amersham,
Arlington Heights, IL) and shrimp alkaline phosphatase
(Amersham) at 37°C for 15 minutes and at 80°C for 15
minutes. Automatic direct DNA sequencing of exon 10 was
done using the AB I Prism Dye Terminator Sequencing Kit
(Perkin Elmer Cetus for PCR products).
Statistical analysis
Analyses of correlations between immunohistochemi-
cal expression of p53 protein, histologic features, and out-
comes were carried out using the Fisher exact test. Analy-
ses of the PCNA proliferation index, expression of the p53
protein, and outcomes were done using the Mann-Whitney
test. A P value < 0.05 was considered statistically signifi-
cant. Recurrence was fixed as event of interest, which was
evaluated by the Kaplan-Meier test, correlated with p53
immunoexpression, PCNA index ≥ 40 and < 40, and sub-




Histologically, the major components of the
osteoblastoma were osteoblast-like cells, stromal cells,
osteoclasts, osteoid tissue deposition, and blood vessels.
These cases were classified as classical osteoblastomas (n
= 23) (Figure 2). Five patients had destructive infiltration
and cortical invasiveness (interruption). In these patients,
the most commonly affected sites were the spine, flat
bones, and long bones. Atypical osteoblastomas were di-
agnosed by the following features: epithelioid osteoblasts
were identified in 5 patients (Figure 3) and a zone of spicu-
lated blue bone,5 was observed in 6 patients (Figure 4).
Figure 2 - Classical histologic aspects of osteoblastoma with long inter
anastomosing trabeculae of woven bone and osteoid rimmed by a single
row of osteoblasts (Case 21, hematoxylin-eosin stain, X 200)
Figure 3 - Atypical osteoblastoma. Epithelioid osteoblasts with eosinophilic
cytoplasm and large vesicular nuclei with prominent nucleoli (Case 28,
hematoxylin-eosin stain, X 400)
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Occasionally, osteoblasts showed a focal clustering pattern
and hyperchromatic nuclear staining (Figure 5). Cases with
features described above were classified as atypical
osteoblastomas (n = 7), and the distinction from osteosar-
coma was based on the absence of atypical mitotic figures,
cellular pleomorphism, neoplastic cartilage, and permeative
growth into adjacent bone tissue.13
p53 immunohistochemistry / gene mutation
Positive immunoexpression of p53 was identified in 4
cases of osteoblastomas (13.3%), with 3 of these classified
as atypical osteoblastoma (Figure 6). Significantly more
cases were p53-positive in atypical tumors (P = 0.03). In
the osteosarcoma group (n = 17), 4 cases were p53-posi-
tive (23.5%). When the 3 groups were compared,
immunoexpression of p53 in atypical osteoblastoma was
similar to that of osteosarcoma, and both were different
from classical osteoblastoma (P < 0.005) (Figure 7). Es-
sentially, expression of the p53 protein was statistically cor-
related with recurrence (P = 0.009), atypical osteoblastoma
classification (P = 0.031), and with the presence of spicu-
lated blue bone (P = 0.018). Mutational changes of the p53
at exon 10 (codon 337) were identified in 3 of 4 patients
with osteoblastoma (2 patients with atypical osteoblastoma,
and 1 patient with classical osteoblastoma) (Figure 8) and
1of 4 patients with osteosarcoma. Exons 5 and 7 could not
Figure 4 - Atypical osteoblastoma. Focal areas of fine, lace-like osteoid
(Case 29, hematoxylin-eosin stain, X 400)
Figure 5 - Atypical osteoblastoma. High cellularity and atypical cells. No
evidence of osteoid production (Case 27, hematoxylin-eosin stain, X 400)
Figure 6 - Atypical osteoblastoma. Immunohistochemical detection of the
p53 protein with DO7. A distinct nuclear reaction is seen the majority of the
tumor cells (Case 26, immunohistochemistry, X 400)
Figure 8 - Direct genomic sequence analysis of the p53 gene in patient
no.30. Heterozygous G to A substitution in exon 10
Figure 7 - Number of patients within the 3 groups classical osteoblastoma
(CO), atypical osteoblastoma (AO), and osteosarcoma (OS), showing positive
and negative immunoexpression for the p53 protein
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be evaluated in the samples because of the limited amount
of adequately sized DNA fragments obtained from the ar-
chival paraffin embedded tissues, which failed to amplify
by PCR.
PCNA labelling index (PCNA-LI)
The atypical osteoblastoma and osteosarcoma groups
had higher mean PCNA-LI values than those of classical
osteoblastoma (P < 0.001) (Figures 9 and 10). The mean
PCNA indexes for classical osteoblastoma, atypical
osteoblastoma, and osteosarcoma were 33.7%, 61.7%, and
79.3%, respectively. Results were divided into 2 groups:
low PCNA index (< 40%) and high PCNA index (≥ 40%)
(30 patients)
Correlation between clinical outcome, osteoblastoma
classification, p53 expression, morphological
parameters, and PCNA labelling index
The clinical data of 30 patients were available with a
48-month period of follow-up. All patients were treated by
total surgical ressection. Five patients (16.6%) had recur-
rence of the tumor. Three of the patients were in the group
with atypical osteoblastoma. Analysis by the Kaplan-Meyer
test showed that recurrence was statistically correlated with
the atypical osteoblastoma subgroup (P = 0.031), (Figure
11), p53 protein expression (P = 0.009), (Figure 12), pres-
ence of spiculated blue bone (P = 0.041), and PCNA la-
belling index stratified by a 40% cut-off value (P = 0.015)
(Figure 13).
DISCUSSION
The accurate detection and differentiation and treatment
of benign and malignant bone tumors can be a serious chal-
lenge. 27,28 The histologic appearance of osteoblastoma var-
ies widely. At one end of the spectrum are the lesions char-
acterized by trabecular organization of the newly formed
Figure 12 - Kaplan-Meier test for event recurrence, comparing p53
immunoexpression positive and negative
Figure 10 - PCNA% in classical osteoblastomas (1.0), atypical
osteoblastomas (2.0), and osteosarcomas (3.0)
Figure 9 - Mean values of PCNA labeling indexes in classical osteoblastoma,
(33.7%) atypical osteoblastoma (61.7%), and osteosarcoma. (79.3%)
Figure 11 - Kaplan-Meier test for event recurrence, comparing subgroups
of osteoblastoma (atypical osteoblastoma and classical osteoblastoma)
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osteoid, highly vascular background, and low cellularity.
At the other end of this spectrum are the lesions charac-
terized by high cellularity, prominent blue osteoid, mito-
sis, and epithelioid osteoblasts. These cases may be desig-
nated as atypical or aggressive osteoblastomas. In our study,
the presence of a lace-like or a sheet-like osteoid deposi-
tion was correlated with recurrence (P = 0.041) and ag-
gressive behavior. As with other series, the aggressive pat-
tern of this tumor entity was not correlated with other his-
tological features, such as the evidence of epithelioid
osteoblasts and infiltrative histologic growth.1,14
The recurrence rate presented in this series of patients
(16.6%) was similar to that of earlier observations.14 The
PCNA-LI was correlated with recurrence and the highest in-
dices were associated with atypical groups, as observed in
the osteosarcoma group. A PCNA-LI < 40% was rarely found
in atypical osteoblastoma (1/7) or osteosarcoma (0/17).
The frequency of p53 immunostaining varied among the
different subtypes of osteoblastoma and osteosarcoma, be-
ing observed predominantly in osteosarcoma and in atypi-
cal osteoblastoma. Interestingly, out of the 2 classical
osteoblastomas associated with recurrence, 1 was positive
for p53 immunostaining and showed a DNA mutation in
exon 10. This is the first study that shows DNA mutation
at exon 10 in osteoblastomas. Other studies have also re-
ported p53 mutations and the immunohistochemical pro-
tein detection.22,29-31 Immunopositivity for p53 was detected
in cases that did not have evidence of p53 gene mutation.
This may have occurred for several reasons, including that
Figure 13 - Kaplan-Meier test for event recurrence, comparing PCNA
labeling index ³40 and < 40
mutational changes of p53 gene may occur outside the re-
gion of the gene analyzed. In this study, Exon 5 and exon
7 were not evaluated in all the samples because the size of
the amplified fragments is restricted in archival paraffin-
embedded tissues. The quality of DNA extracted from this
sort of sample is highly variable, and it depends on decal-
cification, fixing, and storing of the tissues samples.32
The sample size of the current study was too small to
draw definitive conclusions regarding the relationship be-
tween clinicopathologic features and p53 changes. How-
ever, the results indicating that atypical osteoblastoma, as
described by its morphological features, seems to be a real
entity. When evaluated by means of proliferation rate and
p53 mutations, atypical osteoblastoma exhibits a behavior
that is in between classical osteoblastomas and
osteossarcomas. The major diagnostic challenge is in dif-
ferentiating malignant or aggressive osteoblastoma from
osteosarcoma on the basis of the pathologic features,since
the diagnosis markedly changes treatment in patients.33,34
None of our cases presented metastases. These findings
raise the possibility that new genetic events may occur in
the group of osteosarcomas that are responsible for its abil-
ity to acquire metastatic potential. Our results suggest that
the detection of p53 immunopositivity, evidence of a high
PCNA labeling index (³ 40), and mutations of the p53 gene
(exon 10) may have a role in the pathogenesis of
osteoblastomas and may reflect the tumoral progression
with recurrences, but not exert a sufficient deleterious ef-
fect to produce malignant behavior, as is observed in oste-
osarcoma.
Thus, further investigation, including that regarding
functional analysis of mutations, is essential to demonstrate
the role of genetic changes in the clinical and histopatho-
logic features of osteoblastoma.
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RESUMO
Oliveira CRGCM de, Mendonça BB, Camargo OP de, Pinto
EM, Nascimento SAB, Latorre M do RDO, Zerbini MCN.
Osteoblastoma clássico, osteoblastoma atípico e osteos-
sarcoma. Um estudo comparativo baseado em parâmetros
clínicos, histológicos e biológicos. Clinics. 2007;62(2):
167-74.
OBJETIVOS: Investigar o comportamento biológico de
osteoblastomas clássicos e atípicos comparados com
osteossarcomas.
MÉTODOS: Com base em parâmetros histológicos clas-
sificamos um grupo de 30 osteoblastomas nos subgrupos
de osteoblastomas clássicos (23/30) e de osteoblastomas
atípicos (que apresentam como característica grande
celularidade, osteóide azul proeminente e osteoblastos
epitelióide—7/30). Como efeito de comparação dos resul-
tados imunohistoquímicos e análise clínica, avaliamos 17
pacientes com osteosarcoma de grau avançado. Os cortes
histológicos com bloco de parafina fixado em formalina
foram imunocorados para p53 e antígeno nuclear de célu-
la em proliferação. Tumores com coloração positiva para
p53 tiveram análise molecular para fragmentos do exon 10.
RESULTADOS: O índice médio de antígeno nuclear de cé-
lula em proliferação para osteoblastoma clássico,
osteoblastoma atípico e osteosarcoma foram de 33%, 61% e
79%, respectivamente. O subgrupo atípico demonstrou resul-
tados similares aos dos osteosarcomas (p<0,001). Foram de-
tectadas proteína p53 em 4 (13%) osteoblastomas; 3 desses
foram osteoblastomas atípicos, sendo que 4 osteosarcomas
(23%) também demonstraram p53 positivo. A mutação do
DNA nos casos positivos de p53 foi confirmada no exon 10
em dois osteoblastomas atípicos (2/3), um osteoblastoma clás-
sico (1/1) e um osteosarcoma (1/4). A recorrência da doença
foi correlacionada com a expressão do p53 (p=0,009), subtipo
atípico (p=0,031), osso azul espiculado no resultado da
histologia (p=0,018), e índice de marcação pelo antígeno nu-
clear de célula em proliferação ≥ 40 (p=0,015).
CONCLUSÃO: Esses resultados validam os osteoblas-
tomas atípicos como entidade real, com imunoexpressão
das proteínas p53 e antígeno nuclear de célula em prolife-
ração mais perto do osteosarcoma do que do osteoblastoma
clássico. O índice de marcação pelo antígeno nuclear de
célula em proliferação e o p53 podem ser úteis fatores de
prognóstico da recorrência.
UNITERMOS: Neoplasias ósseas. Proliferação celular.
PCNA. Imunohistoquímica. Osteoblastoma. Proteína p53.
Gene p53.
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